Antares Pharma today reported it received a Notice of Allowance from the U.S. Patent Trade Office on a patent application for the VIBEX QuickShot device. This device is the latest advancement in its proprietary line of VIBEX auto-injector systems.
The VIBEX QuickShot device offers a dose capacity of up to 1 milliliter and the design can be scaled for larger volumes. Its design puts an emphasis on enhanced performance with attributes most critical to patient success – speed, comfort, and discretion. The new design also accommodates fast injection of highly viscous drug products that stall less powerful, conventional auto-injectors. This is key since many self-injectable agents on the market are administered in a 1 milliliter dose and are of higher viscosity.
Antares Pharma president and CEO, Paul K. Wotton, Ph.D., is pleased that the size and scope of the company’s intellectual property continues to grow; especially so since he believes that many injectable drugs currently under development will be taken via the self-injection method. Therefore, Antares’ products may be critical for the growing number of chronic care products that can be given only by injection.
Antares Pharma is a specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA-approved products. The company’s products improve safety and efficacy by minimizing dosing and reducing side effects while improving patient compliance.
For additional information about Antares and its product portfolio, visit www.antarespharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
